Eagerly awaiting the opening of the San Antonio Breast Cancer Symposium (SABCS), Kathy D. Miller, MD, surveys the many study results scheduled to be announced.
Citing the TALENT, RIGHT Choice, POSITIVE, and EMERALD trials, Dr Miller comments on a range of issues in breast cancer, reaching from the early-stage to the metastatic settings and involving such clinical concerns as pregnancy outcomes in patients with ER-positive disease, the advent of HER2-low as an independent disease category, the possible place of selective estrogen receptor downregulators (SERDs) in standard treatments, and the comparative benefits of hormone therapy together with ribociclib vs chemotherapy in younger patients.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: SABCS 2022: Anticipating an Abundance of Data - Medscape - Dec 19, 2022.
Comments